Documenti fondamentali

Visualizza tutta la documentazione

Vai a

SML0150

Tolcapone

Name: Tolcapone
Brand: SIGMA
Price: 86.7 CHF

≥98% (HPLC), Catechol-O-methyltransferase inhibitor, powder

Sinonimo/i:

3,4-Dihydroxy-4′-methyl-5-nitrobenzophenone, Ro 40-7592

Autenticati per visualizzare i prezzi organizzativi e contrattuali.

Scegli un formato

Cambia visualizzazione

Voi/SKU	Disponibilità	Prezzo
10 mg	Per conoscere la disponibilità, visualizza il carrello	CHF 86.70
50 mg	Per conoscere la disponibilità, visualizza il carrello	CHF 343.00

Informazioni su questo articolo

Formula empirica (notazione di Hill):

C₁₄H₁₁NO₅

Numero CAS:

134308-13-7

Peso molecolare:

273.24

UNSPSC Code:

12352200

PubChem Substance ID:

329825198

NACRES:

NA.77

MDL number:

MFCD00866569

Assay:

≥98% (HPLC)

Form:

powder

Storage condition:

desiccated

CHF 86.70

Per conoscere la disponibilità, visualizza il carrello

Richiedi un ordine personalizzato

Servizio Tecnico

Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.

Permettici di aiutarti

Proprietà

Nome del prodotto

Tolcapone, ≥98% (HPLC)

Quality Segment

100

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

yellow

solubility

DMSO: ≥15 mg/mL

originator

Roche

storage temp.

2-8°C

SMILES string

Cc1ccc(cc1)C(=O)c2cc(O)c(O)c(c2)[N+]([O-])=O

InChI

1S/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3

InChI key

MIQPIUSUKVNLNT-UHFFFAOYSA-N

Gene Information

human ... COMT(1312)

Descrizione

Application

Tolcapone may be used in COMT-mediated cell signaling studies.
Tolcapone has been used in methyltransferase assay in human embryonic kidney 293 cells.

Biochem/physiol Actions

Orally active catechol-O-methyltransferase (COMT) inhibitor: inhibits both central and peripheral COMT.

Tolcapone is an orally active catechol-O-methyltransferase (COMT) inhibitor. It inhibits both central and peripheral COMT. Tolcapone crosses the blood-brain barrier, and has been used for L-DOPA adjunct therapy in the treatment of Parkinson′s Disease.

Inhibition of catechol-O-methyltransferase by tolcapone increases the half-life and bioavailabilty of levodopa. It therefore is an effective adjunctive therapy in patients with Parkinson′s disease with motor response fluctuations.

Features and Benefits

This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Confronta articoli simili

Visualizza il confronto per intero

Mostra le differenze

1 of 1

Questo articolo	1670207	T7080	R108
Sigma-Aldrich SML0150 Tolcapone	USP 1670207 Tolcapone	Sigma-Aldrich T7080 Tazarotene	Sigma-Aldrich R108 Ro 41-0960
description ≥98% (HPLC)	description United States Pharmacopeia (USP) Reference Standard	description ≥98% (HPLC)	description solid
assay ≥98% (HPLC)	assay -	assay ≥98% (HPLC)	assay -
form powder	form -	form powder	form solid
Quality Level 100	Quality Level -	Quality Level 100	Quality Level 100
storage temp. 2-8°C	storage temp. -	storage temp. 2-8°C	storage temp. 2-8°C
solubility DMSO: ≥15 mg/mL	solubility -	solubility DMSO: >15 mg/mL	solubility H₂O: slightly soluble <0.7 mg/mL, ethanol: soluble, 45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 1.0 mg/mL
storage condition desiccated	storage condition -	storage condition -	storage condition protect from light

Still not finding the right product?

Explore all of our products under Tolcapone

Pittogrammi

GHS09

Parola di avvertenza

Warning

Codici di pericolo

H400

Avvertenze di sicurezza

P273 - P391 - P501

Hazard Classifications

Aquatic Acute 1

Classe di stoccaggio

11 - Combustible Solids

Che succede?

WGK 3

Punto di infiammabilità (°F)

Not applicable

Punto di infiammabilità (°C)